 Artist: Split Lip Rayfield: mp3 download Genre(s): Other Discography:  Should Have Seen It Coming Year: 2004 Tracks: 16  Never Make It Home Year: 2001 Tracks: 14  In The Mud Year: 1999 Tracks: 16 The Kansas-based post-punk progressive bluegrass outfit Split Lip Rayfield was comprised of vocalist/banjoist David Lawrence, guitarist/dobroist Kirk Rundstrom, and one-string bassist Jeff Eaton, whose instrumental role was fashioned from the accelerator cooler of a 1965 Ford. An offset of the mathematical group Scroat Belly (though it didn't take long for them to outlive the dance orchestra that spawned them), the trio debuted in 1998 with a self-titled LP issued on the Bloodshot label. In the Mud followed a year after; by this time, isaac Bashevis Singer and mandolin player Wayne Gottstine had expanded the batting order of magnitude to four-spot pieces and Eric Mardis had replaced Lawrence on banjo. The new millennium saw the release of a third base military campaign, Never Make It Home, which arrived in stores in late 2000. After trinity eld of touring, which byword the mathematical group opening for everyone from Del McCoury to Nashville Pussy, Split Lip Rayfield recorded and released a fourth long-player, Should Have Seen It Coming, in 2004. In early 2006, Rundstrom (world Health Organization had likewise released a few solo records) was diagnosed with crab. He continued to perform with the band for months as he fought and underwent intervention, only Rundstrom in the end succumbed to the disease in February 2007, just around a workweek afterwards playacting what would be his final establish. |
Monday 25 August 2008
Download Split Lip Rayfield mp3
Friday 15 August 2008
Biota Holdings Limited (ASX:BTA) Commences Human Rhinovirus Phase IIa Clinical Trial
�Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) announced the commencement of dosing in the first base Phase IIa challenge report of BTA798, an orally delivered and potent inhibitor of human rhinovirus (HRV). HRV is the major cause of the unwashed cold and is associated with clinical complications for patients with asthma, cystic fibrosis, continuing obstructive pulmonic disease or a compromised immune use.
The purport of the Phase IIa study is to assess BTA798 for the bar (prophylaxis) of HRV infection in or so 200 intelligent volunteers. Each volunteer volition be administered either placebo or i of trey dose levels of BTA798 before being exposed to an experimental rhinovirus infection.
The double blind study will be conducted in a controlled quarantine facility in the UK and will monitor the clinical endpoints of viral count and cold symptom improvement. Drug safety and pharmacokinetics volition also be monitor! ed to provide further information on BTA798.
The results o! f this a nd subsequent Phase IIa studies will be used to assist in selecting doses for treatment and prevention of HRV infection in later clinical studies.
Dosing is expected to be completed by December/January, subject to adequate enrolment rates with volunteers. The full results are expected by the end of April 2009.
About Phase IIa challenge studies
Challenge studies with antiviral agent drugs expose volunteers to both an induced infection and the drug under study. Challenge studies may examine the efficacy of the drug to either treat the infection (therapy) or prevent the infection (prophylaxis) and the potency of the drug normally is deliberate by compare to a placebo . Therapeutic challenge studies require the infection to be naturalized before do drugs treatment and prophylactic challenge studies ask the commencement of do drugs treatment before exposure to the induced infection.
Volunteers included in challenge studies must be both he! althy and potentially susceptible to the induced infection.
Biota's initial trial is a prophylaxis study with volunteers exposed to HRV infection by intranasal inoculation.
About human rhinovirus, including in Asthma & COPD
Rhinoviruses can causal agency up to 50% of all adult colds, and are the predominant cold virus in children. In otherwise healthy individuals, rhinovirus infections ar a nonaged inconvenience and are self limiting, although 75% of common colds suffered by children under 5 years of historic period in the US, are medically tended to.
However, HRV is a major cause of hospitalization and respiratory distress in individuals with chronic fundamental respiratory conditions, including bronchial asthma and COPD sufferers.
It is estimated that rhinovirus is associated with or so 70% of all asthma exacerbations and more than 50% of the hospitalised cases. Although the actual costs of viral exacerbations in asthma attack have not been ! measured, they appear to put up significantly to the tot up! cost of the disease, as they represent some 80% of exacerbations in children and between 40% and 76% in adults.
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the US. An estimated 10 million adults were diagnosed with COPD in 2000, while a national health survey suggests that as many as 24 million Americans ar affected. In 2000, 119,000 deaths, 726,000 hospitalisations and 1.5 million hospital emergency department visits were caused by COPD in the US. Studies suggest that respiratory viruses ar associated with more than 35% of acute exacerbations of COPD requiring hospital care.
About Biota Holdings Limited
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.
Biota res! earch breakthroughs make included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, accredited to MedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, accredited to Boehringer Ingelheim. Biota has clinical trials underway with its lead deepen for human rhinovirus (HRV) infection in patients with compromised internal respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second propagation influenza antivirals. Inverness Medical markets Biota's co-developed OIA FLU flu diagnostics.
Relenza(tm) is a registered trademark of the GlaxoSmithKline radical of companies.
BioStar(R) OIA(R) FLU and BioStar(R) OIA(R) FLU A/B are registered trademarks of Inverness Medical.
Biota Holdings Limited
View drug information on Relenza.
More info
The purport of the Phase IIa study is to assess BTA798 for the bar (prophylaxis) of HRV infection in or so 200 intelligent volunteers. Each volunteer volition be administered either placebo or i of trey dose levels of BTA798 before being exposed to an experimental rhinovirus infection.
The double blind study will be conducted in a controlled quarantine facility in the UK and will monitor the clinical endpoints of viral count and cold symptom improvement. Drug safety and pharmacokinetics volition also be monitor! ed to provide further information on BTA798.
The results o! f this a nd subsequent Phase IIa studies will be used to assist in selecting doses for treatment and prevention of HRV infection in later clinical studies.
Dosing is expected to be completed by December/January, subject to adequate enrolment rates with volunteers. The full results are expected by the end of April 2009.
About Phase IIa challenge studies
Challenge studies with antiviral agent drugs expose volunteers to both an induced infection and the drug under study. Challenge studies may examine the efficacy of the drug to either treat the infection (therapy) or prevent the infection (prophylaxis) and the potency of the drug normally is deliberate by compare to a placebo . Therapeutic challenge studies require the infection to be naturalized before do drugs treatment and prophylactic challenge studies ask the commencement of do drugs treatment before exposure to the induced infection.
Volunteers included in challenge studies must be both he! althy and potentially susceptible to the induced infection.
Biota's initial trial is a prophylaxis study with volunteers exposed to HRV infection by intranasal inoculation.
About human rhinovirus, including in Asthma & COPD
Rhinoviruses can causal agency up to 50% of all adult colds, and are the predominant cold virus in children. In otherwise healthy individuals, rhinovirus infections ar a nonaged inconvenience and are self limiting, although 75% of common colds suffered by children under 5 years of historic period in the US, are medically tended to.
However, HRV is a major cause of hospitalization and respiratory distress in individuals with chronic fundamental respiratory conditions, including bronchial asthma and COPD sufferers.
It is estimated that rhinovirus is associated with or so 70% of all asthma exacerbations and more than 50% of the hospitalised cases. Although the actual costs of viral exacerbations in asthma attack have not been ! measured, they appear to put up significantly to the tot up! cost of the disease, as they represent some 80% of exacerbations in children and between 40% and 76% in adults.
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the US. An estimated 10 million adults were diagnosed with COPD in 2000, while a national health survey suggests that as many as 24 million Americans ar affected. In 2000, 119,000 deaths, 726,000 hospitalisations and 1.5 million hospital emergency department visits were caused by COPD in the US. Studies suggest that respiratory viruses ar associated with more than 35% of acute exacerbations of COPD requiring hospital care.
About Biota Holdings Limited
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.
Biota res! earch breakthroughs make included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, accredited to MedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, accredited to Boehringer Ingelheim. Biota has clinical trials underway with its lead deepen for human rhinovirus (HRV) infection in patients with compromised internal respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second propagation influenza antivirals. Inverness Medical markets Biota's co-developed OIA FLU flu diagnostics.
Relenza(tm) is a registered trademark of the GlaxoSmithKline radical of companies.
BioStar(R) OIA(R) FLU and BioStar(R) OIA(R) FLU A/B are registered trademarks of Inverness Medical.
Biota Holdings Limited
View drug information on Relenza.
More info
Thursday 7 August 2008
Dallas Opera co-founder Rescigno dies in Italy
ROME �
More information
Nicola Rescigno, the cofounder of the Dallas Opera and one of Maria Callas' favourite conductors, has died at a hospital in Italy, officials said Tuesday. He was 92.
Rescigno died Monday of complications following spirit failure and breathing problems, said Corrado Ricci, a doctor at the Belcolle hospital in Viterbo, a town about 50 miles north of Rome. Rescigno had been admitted on July 30 with a broken femoris, following a fall. But Ricci aforesaid that at that point, he was already in serious condition.
Jonathan Pell, the Dallas Opera director of artistic administration, said he received a call Monday afternoon from Rescigno's nephew, who had been informed of his uncle's death by the hospital.
Pell said Rescigno "went to sleep and didn't wake up."
The New York-born Rescigno stirred to music after a receiving a law arcdegree at Rome's La Sapienza university. His career was largely spent in the United States.
He conducted Callas' debut in America, eventually becoming one of the star soprano's favorite conductors throughout a cooperation that spanned several years, performances and recordings.
"He knew how to make for together orchestra and vocalizing, doing everything possible to bring out the best singing performance," said Elvio Giudici, a leading opera house critic. "It is not by chance that he worked with Callas when she had her lowly vocal problems."
Rescigno and the late Lawrence V. Kelly founded the Dallas Opera in 1957, with Rescigno taking the job of artistic director.
According to the theater's Web site, the theater open with a concert by Callas in November of that year.
After Kelly's death in 1974, Rescigno took on the role of general director as well.
Rescigno was as well a cofounder of the Lyric Opera of Chicago and conducted at the Royal Opera Covent Garden, Metropolitan Opera and Vienna State Opera. His recordings include recitals with Callas and Luciano Pavarotti.
During his career, Rescigno also toured some of the most important opera theaters in Italy, including Rome's Opera House, the San Carlo in Naples and La Fenice in Venice.
"He was of the old school. He knew the repertory backwards," aforesaid Giudici. "He could figure out any trouble because he knew the subject actually well."
"Adjust the sound, the orchestra, the timing, the dynamics to the atmospheric condition of whatever given night: this is something that old-time directors could do really well," said Giudici.
Pell said plans to laurels Rescigno by the Dallas Opera volition be proclaimed later.
---
On the Net:
http://www.dallasopera.org
More information
Subscribe to:
Posts (Atom)